International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010

PHASE3CompletedINTERVENTIONAL
Enrollment

700

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

July 31, 2023

Study Completion Date

July 31, 2023

Conditions
Acute Lymphoblastic Leukemia (ALL)
Interventions
DRUG

SR-A + Epratuzumab

DRUG

SR-B + Epratuzumab

Trial Locations (17)

1020

Hòpital Universitaire des Enfants Reine Fabiola, Brussels

1090

St. Anna Kinderkrebsforschung, CCRI, Vienna

2100

Copenhagen University Hospital (Rigshospitalet), Copenhagen

3168

Australian & New Zealand Childhood Hematology & Oncology Group, Clayton

8032

University Children's Hospital Zurich, Zurich

13353

Charité - Universitätsmedizin Berlin, Berlin

50354

Dpt. SCT and Hematology/Oncology University Wroclaw, Wroclaw

64239

Tel Aviv Sourasky Medical Centre, Tel Aviv

Unknown

University Hospital Motol, Prague

CHU Nice, Nice

St.Lukes International Hospital, Tokyo

Prinses Máxima Centrum, Lundlaan, Utrecht

Instituto Português de Oncologia de Lisboa, Lisbon

SF-20520

Turku University Central Hospital, Turku

00165

Ospedale Pediatrico Bambino Gesù, Roma

0027

Oslo University Hospital, Oslo

M13 9WL

Royal Manchester Children's Hospital, Manchester

All Listed Sponsors
collaborator

Australian & New Zealand Children's Haematology/Oncology Group

OTHER

collaborator

St. Anna Kinderkrebsforschung (Co-Sponsor Austria)

UNKNOWN

collaborator

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

collaborator

University Hospital Motol (Co-Sponsor Czech Republic)

UNKNOWN

collaborator

Copenhagen University Hospital (Rigshospitalet) (Co-Sponsor Copenhagen)

UNKNOWN

collaborator

Turku University (Co-Sponsor Finland)

UNKNOWN

collaborator

Centre Hospitalier Universitaire de Nice

OTHER

collaborator

Our Lady's Chilrden's Hospital (Co-Sponsor Ireland)

UNKNOWN

collaborator

Tel Aviv Sourasky Medical Centre (Co-Sponsor Israel)

UNKNOWN

collaborator

Ospedale Pediatrico Bambino Gesù (Co-Sponsor Italy)

UNKNOWN

collaborator

National Hospital Organization Nagoya Medical Center (Co-Sponsor Japan)

UNKNOWN

collaborator

Prinses Máxima Centrum (Co-Sponsor Netherlands)

UNKNOWN

collaborator

Oslo University Hospital (Co-Sponsor Oslo)

UNKNOWN

collaborator

Medical University of Wroclaw (Co-Sponsor Poland)

UNKNOWN

collaborator

Instituto Português de Oncologia de Lisboa (Co-Sponsor Lisboa)

UNKNOWN

collaborator

Spanish Society of Pediatric Hematology and Oncology (SEHOP) (Co-Sponsor Spain)

UNKNOWN

collaborator

University Children's Hospital, Zurich

OTHER

collaborator

Central Manchester University (Co-Sponsor United Kingdom)

UNKNOWN

lead

Charite University, Berlin, Germany

OTHER

NCT01802814 - International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 | Biotech Hunter | Biotech Hunter